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Abstract:
Background:
Genetic research has become an indispensable instrument for medical research, and the subjects involved have both divergent and convergent
interests.
Objective:
The possibility of having more detailed genetic information undoubtedly offers benefits for the health of the subject, but could also pose risks and
make the subject vulnerable to discrimination.
Methods:
The scientific community has viewed very favorably the public health utility of family history, in which data from a family whose members suffer
from chronic pathologies is collected and filed, in order to develop a sort of “stratification of family risk.”
Even though in the last decade the scientific and juridical literature has contributed greatly to the topic of biobanks, the perplexities that continue to
surround this theme give the idea that current ethical protocols on research are inadequate.
Results:
Researchers, citizens, International stakeholders, mass media, Public Health and Governments play a key role in genetic research. It is obvious that
the methods used for genetic research do not present intrinsic risks; they are much less dangerous than other activities of diagnosis and research.
Before authorizing a research project, it is important to reflect on the responsibility and transparency of the studies to be conducted, and on the
impact they may have on the interests of public health.
Conclusion:
We believe that the highest priority need is to develop a common language on the theme, as is the case in the sphere of clinical experimentation
where rules of good clinical practice, albeit at times conflicting, have led to uniform convergences in the scientific world on the points to be
actuated.
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1. INTRODUCTION
DNA is “the deepest and most essential patrimony of the
human person” [1], because it is shared with other people from
the same geographical area. It may predict future events or the
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possibility that may occur. It is easy to obtain, and can be of
interest to third parties [2] such as family members, insurance
companies and employers.
Therefore, there is great interest in this information, espe-
cially  since  genetic  predisposition  has been  clearly  demons-
trated for various diseases such as cardiovascular pathologies
[3, 4] diabetes [5], late onset Alzheimer [6], schizophrenia [7]
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bipolar  disorder  [8],  autism  [9],  cancer  [10  -  12]  and  rare
diseases [13].
The collections of tissues derived from human bodies and
used for the extraction of genetic material have become known
under  various  names  such  as  biobanks,  biolibraries,  tissue
repositories,  genetic  databases,  or  DNA  banks.
The OECD defined human biobanks and genetic research
databases  as  ‘structured  resources  that  can  be  used  for  the
purpose of genetic research, which includes human biological
materials and/or information generated from the analysis of the
same; and extensive associated information [14]
Samples  used  for  genetic  diagnoses  or  purposes  closely
related to genetic data are collected in a genetic biobank [15].
These  collections  have  the  particular  characteristic  that  the
identity  of  the  donor  can  be  connected  to  his/her  personal,
genealogical and clinical data.
The purpose of genetic biobanks [15] is to support research
to identify the mutations that cause genetic diseases, since they
permit researchers to collect material from families affected by
the  same pathology,  with  an enormous saving of  energy and
funds.
There has been an acceleration in the study of  “complex
diseases”  [16]  whose  etiopathogenesis  involves  both  genetic
and  environmental  factors,  as  the  existence  of  biobanks  has
enabled  greater  comprehension  of  pathogenetic  mechanisms,
development of new diagnostic instruments and the design of
treatment  strategies  [17].  The  enormous  number  of  samples
available has made it possible to identify a distinction between
“susceptibility” and “genetic causality.”
Another particularly fertile field for genetic research is that
of  chronic  pathologies.  The  Evaluation  of  Genomic  Appli-
cations in Practice and Prevention  (EGAPP) [18], created in
2004 by the CDC National Office of Public Health Genomics
in the United States, has studied the genetic aspects of many
tumoral pathologies by referring to samples in biobanks, with
good applicative outcomes.
At  the  same  time,  when  biobanks  facilitate  the  study  of
various factors of genetic risk related to an illness, they poten-
tially influence the societal conceptions of responsibility, group
identity and future options [19].
In  fact,  new  quandaries  emerge  when  genetic  research
identifies groups of subjects who carry genes that place them at
higher risk for a disease. These “individuals at risk” fall into a
disease  category  that  is  ambiguous  because  of  the  slippage
between the risk factor and the disease itself [20]: they are not
ill, but may become so. How should they be treated? As sick
people? As healthy people at risk? Should they be counselled
not to have children? Should they be subjected to higher health
insurance  premiums?  Epistemic  change  influences  cultural
change, and in this case can lead to the creation of a cultural
current that views genetic research with suspicion.
In the scientific literature, genetic exceptionalism [21, 22]
is  the  line  of  thought  according to  which all  the  information
derived from DNA, because of the intrinsic characteristics of
the genetic patrimony, must be considered a separate category
from the  common  information  that  can  be  deduced  from in-
depth  family  anamnesis,  and  should  be  afforded  particular
protection.
The need for genetic privacy [23] is fueled by the fear of
discrimination, social stigmatization, family problems, loss of
control of one’s identity, as well as the psychological implica-
tions, because genetic information can be “potentially embarra-
ssing and uniquely personal” [24].
This  issue  entails  not  only  political  but  even  more
importantly ethical and social choices, because the fundamental
rights  of  the  person  are  involved,  as  well  as  individual  and
collective interests.
2. METHODS
In  this  work,  we  will  discuss  the  role  that  researchers,
physicians, ethics committees, citizens, public health officials
and international stakeholders can play in the promotion and
control of genetic research that draws upon biobanks. We will
examine the current situation in Italy and compare it with that
of other Western countries.
3. RESULTS AND DISCUSSION
3.1.  Physicians/Investigators  (And  Research  Ethics
Committee)
To  date,  the  lack  of  a  common  legislative  framework  in
Europe and the world has allowed local  researchers conside-
rable  independence,  but  has  limited  the  ability  to  create
transnational biobanks [25], a significant exception being the
EuroBioBank,  “a  network  of  biobanks  that  stores  and
distributes quality DNA, cell and tissue samples for scientists
conducting research on rare diseases genetic material and rare
diseases” [26].
However, recent years have seen a growing awareness that
transnational collaboration is essential researchers have access
to a greater quantity of biological samples. It is no coincidence
that  in  the  recent  years  there  has  been  an  increase  in  the
number of transnational associations and entities involved with
genetics,  which  permit  the  circulation  of  ideas  in  various
affiliated nations. An example is the P3G Consortium [27], an
international not-for-profit organization that catalogues experi-
ences  in  the  field  of  population  genetics,  in  order  to  build
common  research  strategies  to  facilitate  harmonization  and
open the door to future collaborations. Another valid example
of openness in this sense is the pan-European Biobanking and
Biomolecular  Resources  Research  Infrastructure  -  European
Research  Infrastructure  Consortium  (BBMRI-ERIC  [28]),
whose  funding  includes  a  grant  from  the  European  Unions’
Horizon 2020 research and innovation program.
In this context, it is noteworthy that in multicentric studies,
data are often collected and then transmitted to third parties.
That  operate  in  different  nations,  which  in  turn  have
different sets of legislation on the subject, but this by no means
exempts those who receive this data from responsibility for the
correct handling of the information. It is extremely important
that the personal data remain the exclusive prerogative of the
research,  and  not  be  exploited  for  purposes  other  than  the
research itself.
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The scientific  community  has  viewed very  favorably  the
public health utility of family history [29], in which data from a
family  whose  members  suffer  from  chronic  pathologies  is
collected and filed, in order to develop a sort of “stratification
of family risk.”
These few examples help us understand how essential it is
to  expand  the  borders  of  genetic  research  to  improve  public
health.
It is obvious that the methods used for genetic research do
not present intrinsic risks; they are much less dangerous than
other activities of diagnosis and research. However, there is an
“information risk” for the patient [30], who may suffer psycho-
logical harm from receiving the genetic test results themselves
or from the way the results are conveyed, or for the patient’s
relatives, since the results may have repercussions for them as
well.
In order to deal with these ethical and legal implications,
North  American  organisations,  followed  by  European  Union
ones,  have  published  guidelines  or  ethical  codes  that  serve
genetic professionals on an international scale. Another issue to
be faced is the problem of incidental findings discovered in the
course of the research. The committees of the Clinical Sequen-
cing  Exploratory  Research  (CSER)  Consortium  and  the
Electronic  Medical  Records  and  Genomics  (eMERGE)
Network [31] asserted that researchers must limit themselves to
informing participants about the research results; they have no
moral obligation to undertake clinical tests on the basis of these
results,  according  to  the  principle  that  clinical  research  is
distinct  from  medical  care  in  both  its  aims  and  its  guiding
moral principles. However, physicians are required to provide
complete information expressed in terms that the subject can
understand. In addition, once the information has been obtained
from the genetic tests, physicians will tend to give more or less
importance to certain data on the basis of their scientific and
cultural formation.
Obviously,  the  problem  is  complicated  in  the  case  of
anonymous samples: on the one hand, donors cannot be infor-
med if  a  genotype at  risk  is  revealed,  but  on the  other  hand,
they do not run the risk that their genetic data may be misused.
Anonymization of data in the constitution of biobanks is of
particular importance because it entails the irreversible loss of
the connection between personal data and genetic information.
The connection constitutes the added value of biobanks. When
biobanks are  established,  the  decision whether  to  anonymize
data  or  not  is  of  crucial  importance.  When  the  connection
between personal data and genetic information is irreversibly
eliminated,  donors  are  protected  from  misuse  of  their
information, However,  it  is  also true that the ability to know
the  identity  of  the  donor  of  a  sample  is  an  added  value,  as
donors can be informed of findings that may prove crucial to
their health and well-being.
The first  to  grasp  the  importance  of  this  aspect  were  the
Scandinavian  nations.  For  example,  a  1999  document  of  the
“Swedish Medical Research Council [32]” defined biobanks as
collections of human tissue samples, the origin of which must
always be traceable. Italy lacks a national law on the subject,
but the 2016 Authorisation for the use of genetic data prepared
by the Guarantor for the Treatment of Personal Data states that
the treatment of genetic data is  allowed only for purposes of
prevention, diagnosis or treatment of the subject, or of scienti-
fic  research,  or  for  purposes of  proof  in  civil  or  penal  cases,
according to the dictates of law.
Thus Italy allows scientific research on genetic material, as
long as it respects the rules set forth in the Authorisation for the
use of genetic data. Instead, there is no specific legislation on
the establishment and use of biobanks.
Of  central  importance  in  this  legislative  vacuum  are  the
ethics committees [33], which evaluate the ethics of studies on
genetic data, and also express opinions on research programs
that involve the study of data or samples when for particular
reasons it is not possible to inform the donors [34 - 36].
Serious vigilance on the part of the Research Ethics Com-
mittee and self-control on the part of researchers are the basis
for credible genetic research that respects human dignity.
3.2. The Role Of Citizens
The  possibility  of  having  more  detailed  genetic  infor-
mation undoubtedly offers potential benefits for the health of
the  subject,  but  could  also  pose  risks  and  make  the  subject
vulnerable to discrimination in cases in which the genotype is
used to draw conclusions about the phenotype.
Early knowledge about one’s own genetic characteristics
and  the  probability  of  contracting  a  pathology  provides  the
basis for taking preventive measures. In the case of a multifac-
torial  disease,  that  is,  one  in  which  there  is  an  association
between environment and genotypic characteristics, steps can
be  taken  to  prevent  the  pathology  by  adopting  changes  in
lifestyle,  diet,  work  and  the  environment  itself.
But  knowledge  of  genetic  information  can  change  an
individual’s self-perception and deeply influence the character
of his or her social organization, in cases in which the genetic
patrimony could be an obstacle to a certain type of work. There
could also be significant implications for family planning. For
example,  if  a  couple  is  aware  that  one  of  them  has  a
predisposition  to  a  genetic  disease,  they  may  choose  not  to
have  children  [37].  Or  when  Non-Invasive  Prenatal  Testing
(NIPT)  are  performed,  information  about  the  fetus  could
induce  a  disproportionate  and  unjust  recourse  to  abortion  in
nations that permit it, becoming a form of biological eugenics
[38, 39] or of “positive eugenics [40]”, the goal of which is to
avoid unfavorable medical conditions [41], rather than impose
a genetic structure on future generations [42].
According  to  the  Denver  Post  [43],  80  to  90  percent  of
women  who  receive  a  positive  result  from  an  amniocentesis
test  for  Down Syndrome choose  to  terminate  the  pregnancy.
Their decision is not made on the basis of a moral evaluation
[44],  but  is  grounded  in  concern  about  how  having  a  Down
Syndrome child will affect their life as a couple.
Clearly, knowledge about the fetus’ state of disability can
give the couple greater awareness of their situation as parents,
whether  they  choose  to  terminate  the  pregnancy  or  prefer  to
continue with the birth of a disabled child.
It  is  fundamental  that  citizens  be  well  informed,  so  that
they will not make extreme choices that lack grounding in valid
science, or worse, refuse to consider genetic testing to under-
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stand their health problems.
The  scientific  community  has  been  reflecting  for  many
years on the need to inform citizens adequately about the issue
of  genetic  research.  In  this  regard,  numerous  international
studies  have  explored  people’s  awareness  about  the  risks  of
genetic engineering, their rights to receive or give information
(including the responsibility to family and society), and their
involvement in public debate on genetics. One example is the
“European COB [45]” - Challenger of Biomedicine, Meetings
and Minds.
The  committees  of  the  Clinical  Sequencing  Exploratory
Research  (CSER)  Consortium  and  the  Electronic  Medical
Records  and  Genomics  (eMERGE)  Network  [46]  assert  that
participants in research, if they have given informed consent,
must be informed of the results of a study and participate in an
appropriate clinical follow up.
It is evident that directly involved citizens, such as those
suffering from neurodegenerative pathologies or cancer [47],
are more likely to donate their  tissues and support the estab-
lishment of biobanks designed to study their pathology, while
the  average  citizen  for  whom this  issue  has  no  relevance,  or
members of ethnic or religious minorities, tend to be reluctant
to participate in genetic studies.
While  it  is  commonly  accepted  that  a  patient  who
participates in a genetic study must be thoroughly informed, it
is not so obvious that average citizens involved in population
studies’ must be educated about the new technologies and their
use, or the risks and benefits to the community they may pose
This  issue  came to  international  attention  in  1996,  when
Icelandic citizens gave explicit consent for an initial collection
of DNA and implicit consent for a second one for the deCODE
Genetics  [48]  study,  which  also  gathered  sensitive  health-
related data archived in the nation’s Health Sector Database.
There  was  international  debate  on  the  importance  of  transp-
arent provision of information so that citizens are fully aware
of the ramifications of their involvement.
Since  2005,  numerous  conferences  on  the  subject  have
been  organized  with  the  participation  of  the  community  of
scientists  and  bioethics  specialists,  and  representatives  of
organizations of patients. The conclusions drawn at these gath-
erings have stressed the need for developments in legislation
and  monitoring  systems.  They  have  also  emphasized  the
importance of avoiding pressure from economic interests and
providing  equal  access  to  treatment.  They  have  stated  that
freedom  of  choice  is  paramount,  and  have  discussed  the
decision-making  powers  of  ethics  committees.
They have pointed out that the lack of public participation
in  the  debate  regarding  new genomic  technologies  [49  -  51]
highlights a deficit in Western democracies, while, conversely,
active involvement promotes social justice, confirming Kant’s
view that all people and their points of view on the issue are
important [52].
If  the  national  healthcare  system  were  able  to  identify
families  or  entire  populations  that  have  a  predisposition  to
certain genetic diseases, it could establish prevention and early
treatment programs for these categories. If, instead, citizens do
not  wish  to  participate  in  genetic  screening  programs,  the
healthcare  authorities  will  not  have  the  data  they  need  for
identifying these predispositions, and consequently the subjects
at risk will not benefit from actions the authorities might have
been able to undertake to identify and treat these categories of
at-risk citizens. By now it is clear that patients need to take on
a key role in genetic research [53], not only because doing so
directly provides material for studies, but also because they can
influence their  governments’  choices about  the research pro-
grams to  be  undertaken  to  improve  the  general  health  of  the
nation.
Certainly, it is not possible to foresee exactly how discove-
ries related to genetics will affect a society. e.g., the pharma-
ceutical industry could bring very effective drugs to the market
but charge exorbitant prices, affordable only to a few citizens.
On the other hand, the total opposite could happen. Therefore,
while  today  it  is  impossible  to  answer  questions  about  dis-
tributive justice, it is nonetheless important that civil society be
aware  of  these  issues  and  observe  future  developments  in
biobank-based research with an eye to this important aspect.
Citizens who make available their own body or health data
when they participate in epidemiological studies or research on
a disease can benefit from the opportunity to know the biolo-
gical  characteristics  of  their  own  state  of  health.  Just  as
important, their choice demonstrates the importance of social
solidarity,  because  their  entire  community  benefits  from  the
knowledge  acquired  from  the  study.  In  fact,  citizenship  in  a
community  is  a  source  of  rights,  but  also  of  responsibilities
toward that community.
The  duty  of  social  solidarity  was  emphasized  by  the
Universal  Declaration  on  the  Human  Genome  and  Human
Rights,  adopted  unanimously  by  UNESCO in  1997 [52,  54],
which is the first document of universal importance in the field
of  bioethics.  It  was  written  to  provide  ethical  and  legal
principles  for  the  promotion  of  freedom  of  research,  human
dignity, solidarity and international cooperation.
Subjects who voluntarily participate in genetic research or
who are invited to participate, because of clinical reasons or for
purposes  of  statistics,  must  be  informed  about  the  conse-
quences of having a genetic test done or not having it done.
Social  solidarity  may  strongly  influence  the  decision  of
citizens  to  participate  in  genetic  research  in  the  interests  of
benefit-sharing.  As  stated  in  the  Declaration  on  the  Human
Genome  [55]  (1997),  “Benefits  from  advances  in  biology,
genetics and medicine, concerning the human genome, shall be
made  available  to  all,  with  due  regard  for  the  dignity  and
human rights of each individual. Freedom of research, which is
necessary for the progress of knowledge, is part of freedom of
thought. The applications of research, including applications in
biology, genetics and medicine, concerning the human genome,
shall seek to offer relief from suffering and improve the health
of individuals and humankind as a whole (art. 12)”.
The  HUGO  Ethics  Committee  [56]  (2000)  approved  a
declaration  on  the  sharing  of  benefits  from  genetic  studies,
which should not only have positive effects for the health of
subjects  involved  in  the  research,  but  also  should  provide
broader  and  more  immediate  gain  for  these  communities  in
terms of  investments  in  welfare  by private  firms that  benefit
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financially from the samples donated.
The HUGO [57] Statement on human genomics databases
(2002)  also  indicates  that  these  biobanks  should  be  “global
public  goods”  and  that  there  should  be  “fair  and  equitable”
distribution of the benefits of research. It also called for recog-
nition  of  the  rights  of  researchers,  institutions  and  business
entities  to  a  “fair  return”  for  their  intellectual  and  financial
contribution (recommendation 6).
On the basis of social solidarity and the duty of subsidiarity
of  citizens who participate  in  genetic  research,  some authors
[58  -  60]  have  proposed  using  biological  samples  for  future
research even without specific informed consent, or when there
is a generalized consent that allows any kind of future research
without specifying the details. In this way, citizens would not
benefit personally from the research but could contribute to the
common good in terms of public health.
Others go much farther, perhaps in doing so undermining
social  solidarity.  Some  authors  have  proposed  dynamic  con-
sent, obtained through the use of new computer technologies to
reach  patients  [61].  This  method  of  acquisition  of  consent,
through a digital communication interface, facilitates two-way
communication  to  stimulate  a  more  engaged,  informed  and
scientifically literate participant population where individuals
can tailor and manage their own consent preferences.
Regardless of the method used to obtain informed consent,
it  is  evident  that  studies  on genetic  material  have significant
ethical-legal and social reverberations, and thus great caution is
required in governing access to the data, as well as in contro-
lling how it may be made public.
Just think of how insurance companies could use genetic
data of members of the genetic underclass [62] (the subclass of
people  who  do  not  have  access  to  healthcare  coverage  for
“genetic”  reasons)  or  how  pharmaceutical  firms  [63]  might
discriminate against less widespread genotypes, for whom bulk
drugs are ineffective: these minorities of individuals with parti-
cular genotypes would end up not receiving drugs specifically
for them.
3.3. Mass Media
In this  context,  according to the Council  of  Europe [64],
the  mass  media  play  an  important  role  in  the  spread  of
information  about  genetics,  and  are  key  to  promoting  the
citizen participation in the discussion on the human genome.
In  the  case  of  the  UK  Biobank  and  that  of  the  Islandic
deCODE  Genetics  project,  the  mass  media  encouraged  the
legitimacy of the existing research infrastructures.
3.4. Public Health And Governments
Since the early 1990s,  the establishment of biobanks has
been considered an attractive economic activity [65] because
the  results  of  scientific  research  based  on  biobank  samples
could serve in drug development, could inform disease preven-
tion policies, and could be useful to insurance corporations in
designing  and  adapting  policies.  The  problem  is  that  this
economic  aspect  can  undermine  the  social  solidarity  that
motivates the donation of these tissues from which genetic data
can be obtained. Economic interests could come to outweigh
the  needs  of  medical  science,  and  thus  the  benefits  of  the
results obtained would not be shared with the very populations
who were the object of the studies.
The  potential  alliance  of  public  healthcare  policies  and
genetic research depends on choices currently being made.
The  task  at  hand  is  certainly  difficult  because  entire
chapters  of  the  education  and  perception  of  scientific
knowledge must be re-written, with the unavoidable emergence
of  new  responsibilities  (who  should  manage  a  national  bio-
bank, and how should it be run?)
A new approach is needed for the classic themes of ethics
such  as  informed  consent  and  data  security,  as  well  as
autonomy  and  privacy  (either  in  an  existential  sense  or  as  a
practical problem of confidentiality [66])
In our opinion, a government-run national biobank would
best protect the interests of the people who donated tissues.
The  literature  on  the  theme  provides  no  uniform  inter-
pretations  of  the  role  of  genetics  in  public  health:  many
countries tend toward total interference of research in the life
of citizens (e.g., Denmark [67, 68], Belgium [69], Iceland, and
Australia  [70])  while  others  have  taken  a  more  prudent
approach, that is, they have not created national infrastructures,
but,  as  in  the  case  of  Italy,  have  many  small  collections  at
public or private institutes.
The difference between the two approaches is substantial.
When  a  national  government  acquires  and  uses  genetic  data
from  its  citizens,  storing  this  information  in  a  national
databank, an individual’s genetic information can serve health
of the entire national community. Instead, when genetic data is
stored and used by a number of many small public or private
institutes, an individual’s genetic information can serve his or
her family and a few involved individuals, such as spouses.
Clearly,  in  both  choices,  it  is  important  to  identify  new
responsibilities  and  opportunities,  not  only  those  gained  but
also those lost [71].
We do not believe that the best choice is “total interfere-
nce” by the government, as in the example of Iceland, in which
a national government gathers genetic data on all  its  citizens
and  uses  this  information  to  define  nationalized  healthcare
initiatives  to  meet  needs  that  may  arise.  Instead,  we  think  it
important  to  promote  the  culture  of  the  establishment  of  a
biobank to obtain useful results for families and all of society.
The greater the number of samples collected in a national
biobank, the more feasible it is for genomic analysis to move
from scientific, clinical, governmental and commercial settings
to  that  of  personalized  genomic  medicine  for  the  nation’s
citizens.  However,  what  will  happen  if  “stratified  medicine”
[71] becomes “stratified markets”? When the potential sales to
certain subgroups or entire nations are too insignificant to merit
investment by pharmaceutical firms, these people could end up
lacking the “personalized genomic medicine” that could cure
their health problems. Would this social injustice be addressed
by  their  governments,  which,  after  all,  promoted  a  national
biobank of its citizens’ biological samples?
Before  authorizing  a  research  project,  it  is  important  to
reflect on the responsibility and transparency of the studies to
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be conducted, and on the impact, they may have on the inte-
rests of public health.
3.5. International Stakeholders
The  theme  of  the  human  genome  has  been  addressed  in
terms of respect for human dignity and the fundamental rights
of the person by numerous international documents, such as the
Recommendation  of  the  Committee  of  Europe  regarding
genetic  data  and  tests  [72],  the  1977  Convention  on  Human
Rights  and  Biomedicine,  the  1997  UNESCO  Universal
Declaration on the Genome and Human Rights, the EU’s 2000
Charter of Fundamental Rights,  the November 1996 Code of
Conduct  of  the  International  Labour  Organization  on  the
protection  of  the  personal  data  of  workers,  the  Helsinki
Declaration of the World Medical Association (June 1964 and
successive  modifications),  and  the  European  Commission
Working Document on Genetic Data adopted March 17, 2004
by  the  Working  Party  for  the  Protection  of  Individuals  with
regard to the processing of personal data.
The  Treaty  on  the  Functioning  of  the  European  Union
(TFUE), in requiring institutions and organisms of the EU, as
well  as  the  member  states,  to  respect  the  free  circulation  of
personal data in the exercise of activities that have to do with
the application of the law of the Union (art. 16) also established
that “independent authorities” (instituted by law CE/2001/45 e
and reasserted by the new Regulation (UE) 2018/1725) should
supervise this.
Even though in the last decade the scientific and juridical
literature has contributed greatly to the topic of biobanks, the
perplexities that continue to surround this theme give the idea
that current ethical protocols on research are inadequate [73].
Now,  as  never  before,  international  organizations  have a
crucial role in delineating the route for correct integration of
genetics in public health.
Stakeholders  can  influence  the  government  and  its
changing  public  healthcare  policy,  but  coordination  between
them at various levels is fundamental.
It  would  be  interesting  to  produce  an  internationally
recognized ethical-legal code of good practice concerning the
use of biological samples, one that would enable all researchers
wherever  they  work  to  gain  access  to  biobanks  in  the  same
way, and that  would establish the same technical  regulations
for the organization of the biobanks. Another idea could be a
“free zone for research,” where the same technical regulations
would  attain,  and  where  the  maximum  protection  of  human
dignity would be ensured. Furthermore, it would be interesting
to establish a European observatory on genetic studies, or even
a  world-level  one,  similar  to  the  observatory  on  clinical
experimentation of drugs managed by the EMA, which would
make  known  the  dimension  of  international  level  genetic
studies, to stimulate transnational debate to make data sharing
successful and sustainable.
CONCLUSION
Genetic research has become an indispensable instrument
for  medical  research,  and  the  subjects  involved  have  both
divergent  and  convergent  interests.
On the one hand, the public wants research to advance so
that gains can be made for the health of everyone and benefits
can be shared, but at the same time, people are frightened by
the  risk  of  possible  discriminatory  uses  of  the  information
acquired. On the other hand, researchers and research institutes
call  for  greater  incentives  for  their  work,  appealing  to  the
principle of solidarity, and at the same time demand the rights
to  exploit  the  intellectual  property  associated  with  their
discoveries.
There  are  also  the  international  stakeholders  whose
excessive protection of information risks are slowing or even
paralyzing scientific progress.
Finally, there are the governments of the individual nations
who,  digging  in  and  waiting  for  greater  clarification  on  the
theme, have failed to legislate appropriately or have abdicated
their role to technical organisms (e.g., the Guarantor in Italy),
without resolving the problem, except in a sectorial way.
In  this  Babel  of  overlapping  and  at  times  conflicting
interests, one risks losing sight of the objective: personalized
medicine that can truly help patients.
Genetic data must be used not to exploit, but to serve the
person. Freedom and responsibility must be the twin guiding
lights  for  establishing  parameters  for  the  use  of  biological
samples.  An  evaluation  of  how  this  technology  impacts  the
various aspects of the future of society is urgently needed.
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